Inside the deadly disease confounding medicine, researchers piecing together clues and the breakthrough that meant survival ...

A tiny antibody component could fundamentally transform the treatment of cystic fibrosis: For the first time, researchers ...

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.

SAQE, an innovative tool achieving over 90% accuracy in diagnosing Hypersensitivity Pneumonitis, a serious lung condition ...

A new study suggests that COVID-19 may slightly increase the risk of lung cancer by triggering a biological chain reaction in ...

Avalyn Pharma's IPO aims to fund inhaled IPF therapies as AP01 shows positive Phase II results. Read the full analysis here.

AllRock Bio, Inc., a clinical-stage biotechnology company focused on advancing impactful therapies for cardiopulmonary and ...

People with interstitial lung diseases who use supplemental oxygen are more than three times as likely to have pulmonary ...

Specific combinations of CT imaging features rather than individual findings alone may improve the accuracy of identifying ...

The Pulmonary Fibrosis Foundation (PFF) today announced its PFF Walk 2026 schedule as the organization celebrates the 10 (th) season of the national fundraising program, which has raised more than $7.